Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study

HIV Medicine

Volumn 11, Issue 3, 2010, Pages 170-177

  Skeie, L ^a   Bugge, H ^a   Negaard, A ^b   Bergersen, B M ^a  

^a Department of Infectious Diseases ^*  (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

HIV; Hyaluronic acid; Lipoatrophy; SubQ

Indexed keywords

HYALURONIC ACID; HYALURONIDASE; RESTYLANE SUBQ; STAVUDINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; FACIAL LIPOATROPHY; FACIES; FEMALE; FOLLOW UP; GLOBAL AESTHETIC IMPROVEMENT SCALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PAIN; PAPULE; PARTICLE SIZE; PRIORITY JOURNAL; RATING SCALE; SELF ESTEEM; SKIN INDURATION; SKIN REDNESS; SKIN SWELLING; SKINFOLD THICKNESS; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADJUVANTS, IMMUNOLOGIC; ANTI-RETROVIRAL AGENTS; BIOCOMPATIBLE MATERIALS; FACE; FACIAL DERMATOSES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; PARTICLE SIZE; PATIENT SATISFACTION; RECONSTRUCTIVE SURGICAL PROCEDURES; SELF CONCEPT; TREATMENT OUTCOME;

EID: 75649096425     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00761.x     Document Type: Article

References (24)

1. Duran S, Saves M, Spire B. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001, 15:2441-2444.
2. Rajagopalan R, Laitinen D, Dietz B. Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy. AIDS Care 2008, 20:1197-1201.
3. Valantin MA, Lanoy E, Bentata M. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. HIV Med 2008, 9:625-635.
4. Ribera E, Paradineiro JC, Curran A. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST Study). HIV Clin Trials 2008, 9:407-417.
5. Bergersen BM, Sandvik L, Ellingsen I, Bruun JN. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive. HIV Med 2005, 6:260-267.
6. Slama L, Lanoy E, Valantin MA. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther 2008, 13:67-76.
7. Sutinen J, Walker UA, Sevastianova K. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 2007, 12:97-105.
8. Mallon PW, Miller J, Kovacic JC. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men-a randomized, placebo-controlled study. AIDS 2006, 20:1003-1010.
9. Carey D, Liew S, Emery S. Restorative interventions for HIV facial lipoatrophy. AIDS Rev 2008, 10:116-124.
10. Levy RM, Redbord KP, Hanke CW. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-l-lactic acid: a prospective 3-year follow-up study. J Am Acad Dermatol 2008, 59:923-933.
11. Eppley BL, Dadvand B. Injectable soft-tissue fillers: clinical overview. Plast Reconstr Surg 2006, 118:98e-106e.
12. Andre P. Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHA - Q-Medical, Sweden) in European countries: a retrospective study from 1997 to 2001. J Eur Acad Dermatol Venereol 2004, 18:422-425.
13. DeLorenzi C, Weinberg M, Solish N, Swift A. The long-term efficacy and safety of a subcutaneously injected large-particle stabilized hyaluronic acid-based gel of nonanimal origin in esthetic facial contouring. Dermatol Surg 2009, 35:313-321.
14. Bugge H, Negaard A, Skeie L, Bergersen B. Hyaluronic acid treatment of facial fat atrophy in HIV-positive patients. HIV Med 2007, 8:475-482.
15. Bechara FG, Gambichler T, Brockmeyer NH, Sand M, Altmeyer P, Hoffmann K. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy. Dermatology 2008, 217:244-249.
16. Rosenberg M. Society and the Adolescent Self-Image 1989, Revised edition, Middleton, CT, Wesleyan University Press
17. Valantin MA, Aubron-Olivier C, Ghosn J. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003, 17:2471-2477.
18. Kates LC, Fitzgerald R. Poly-l-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review. Aesthet Surg J 2008, 28:397-403.
19. Lowe NJ, Grover R. Injectable hyaluronic acid implant for malar and mental enhancement. Dermatol Surg 2006, 32:881-885.
20. Mest DR, Humble G. Safety and efficacy of poly-l-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg 2006, 32:1336-1345.
21. Hamilton DG, Gauthier N, Robertson BF. Late-onset, recurrent facial nodules associated with injection of poly-l-lactic acid. Dermatol Surg 2008, 34:123-126.
22. Malhotra R. Deep orbital Sub-Q restylane (nonanimal stabilized hyaluronic acid) for orbital volume enhancement in sighted and anophthalmic orbits. Arch Ophthalmol 2007, 125:1623-1629.
23. Carruthers A, Carruthers J. Evaluation of injectable calcium hydroxylapatite for the treatment of facial lipoatrophy associated with human immunodeficiency virus. Dermatol Surg 2008, 34:1486-1499.
24. Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-l-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005, 52:233-239.